Dow Jones
35 430,42 +13,44 (+0,04 %) Nasdaq
14 258,49 -23,27 (-0,16 %) Nikkei 225
33 321,22 -87,17 (-0,26 %) EUR/USD
1,0971 -0,0028 (-0,25 %) HANG SENG
16 993,44 -360,70 (-2,08 %) Bitcoin EUR
34 434,69 -218,09 (-0,63 %)
Ipsen S.A. (IPN.PA)
Ipsen S.A.
65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 5 300
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. David Loew | MD, CEO & Director | 2,22M | S.O. | 1967 |
| Mr. Aymeric Le Chatelier | Executive VP & Group CFO | 731,25k | S.O. | 1969 |
| Dr. Aidan Murphy Ph.D. | Executive Vice President of Technical Operations | S.O. | S.O. | 1966 |
| Mr. Craig Marks | Vice-President of Investor Relations | S.O. | S.O. | S.O. |
| Mr. Francois Garnier | Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer | S.O. | S.O. | 1962 |
| Ms. Gwenan White | Executive Vice President of Communications, Public Affairs & Sustainability | S.O. | S.O. | S.O. |
| Mr. Regis Mulot | Executive VP & Chief Human Resources Officer | S.O. | S.O. | 1966 |
| Ms. Dominique Bery | Head of Nordics & Baltics | S.O. | S.O. | 1971 |
| Mr. Bartosz Bednarz D.D.S. | Executive VP and Head of Global Product & Portfolio Strategy | S.O. | S.O. | S.O. |
| Mr. Philippe Lopes-Fernandes CBO | Executive VP & Chief Business Officer | S.O. | S.O. | S.O. |
Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Ipsen S.A. en date du 28 novembre 2023 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 7; Compensation : 6.
